Pegpleranib Sodium

N/A

Report date: 2024/07/09 20:00:06
NME

Base Information

Drug NamePegpleranib Sodium
Drug Alias NamepegpleranibFovistaE-10030E-01AJX-01E +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionPlatelet-derived growth factor subunit B inhibitors
TargetsPlatelet-derived growth factor subunit B
Therapy Area/IndicationsMacular Degenerationvon Hippel-Lindau Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[27] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArchemix CorpOsi Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOphthotech CoNational Eye Institute (Nei)
Active IndicationsN/A
Inactive IndicationsMacular Degenerationvon Hippel-Lindau Disease

Other Information

ATC CodeN/A
Related LinksN/A